DataMeds AI, Inc.
DataMeds AI is a holding company for businesses in pharmaceuticals and healthcare services. Its operations include Wellgistics Pharmacy, which provides general and specialty pharmacy services, fills prescriptions and delivers medications to patients, and Wellgistics LLC, a pharmaceutical wholesaler and third-party logistics provider serving manufacturers and independent pharmacies. The company also operates DelivMeds, a technology platform that facilitates prescription transfers, pharmacy routing, patient support and clinical services through digital tools. Wellgistics Pharmacy makes money through prescription fulfillment and reimbursement from payors and patient copayments. Wellgistics LLC provides pharmaceutical distribution and logistics services to manufacturers and pharmacies. DelivMeds offers hub, clinical and data services, with its stated model involving fees from manufacturers and other channel partners. The company’s main office is in Tampa, Florida; Wellgistics Pharmacy is also located there.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $MEDS in the last 30 days.
See all $MEDS insider activity →DataMEDS AI (MEDS) terminated an IP deal due to market conditions, avoiding share issuance. The company owes no fees and maintains other agreements. The move alters recent transaction plans, with future impact dependent on new deals or clarifications.
DataMEDS AI's subsidiary, Corexa Health, has agreed to supply six peptides recommended by the FDA's advisory committee. Corexa Pharmacy will dispense these compounded peptides starting November 2026, leveraging a network of 6,500+ independent pharmacies. The company aims to collect safety data via its Health Lives Here app, aligning with HHS's updated policy. The U.S. compounding pharmacy market is projected to grow to $31 billion by 2035, according to Precedence Research.
DataMeds AI signed a non-binding LOI with six companies to acquire assets, licenses, and a controlling stake in HLH. The deal, pending approvals, would give the recipients 89.5% ownership, with shares as consideration. Closing is contingent on definitive agreements and a liability cap of $2 million. The LOI also includes royalty and governance terms, with REBOOT's transactions potentially closing separately.
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning MEDS (DataMeds AI, Inc.). Coverage has skewed bullish: 2 bullish, 2 neutral, and 1 bearish.
Recent MEDS coverage spans financial news, mergers & acquisitions and corporate actions.
The termination removes a potential equity dilution and may signal weaker pipeline, likely pressuring the stock.
The agreement expands DataMeds' compounding pharmacy business and could boost top‑line growth.
The LOI could significantly dilute existing shareholders and reshape DataMeds' business, creating upside if the deal closes.
Potential upside as the deal could expand DataMeds' platform and market reach.
The program could add modest new revenue streams but its impact is uncertain and far in the future.
AlphAI scores every news story that mentions MEDS with an AI model for sentiment and relevance, and aggregates insider trades from DataMeds AI, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
DataMEDS AI (MEDS) terminated an IP deal due to market conditions, avoiding share issuance. The company owes no fees and maintains other agreements. The move alters recent transaction plans, with future impact dependent on new deals or clarifications.
1 min readDataMEDS AI's subsidiary, Corexa Health, has agreed to supply six peptides recommended by the FDA's advisory committee. Corexa Pharmacy will dispense these compounded peptides starting November 2026, leveraging a network of 6,500+ independent pharmacies. The company aims to collect safety data via its Health Lives Here app, aligning with HHS's updated policy. The U.S. compounding pharmacy market is projected to grow to $31 billion by 2035, according to Precedence Research.
2 min readDataMeds AI signed a non-binding LOI with six companies to acquire assets, licenses, and a controlling stake in HLH. The deal, pending approvals, would give the recipients 89.5% ownership, with shares as consideration. Closing is contingent on definitive agreements and a liability cap of $2 million. The LOI also includes royalty and governance terms, with REBOOT's transactions potentially closing separately.
1 min readDataMeds AI, Inc. (MEDS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 DataMEDS AI Enters Into Amended and Restated LOI to License and Acquire IP that Enables Goal-Driven Prescription Drug Telehealth, Medical Drones and Healthcare Blockchain Technologies ● Proprietary IP Position Until At Least 2042 to Enable Consolidation of Infrastruc
2 min readDataMEDS AI, Inc. (MEDS) introduced its 'Health Lives Here' Community Respiratory Program, targeting 6,500+ Corexa Health network pharmacies. The program, set to launch in Q4 2026, aims to improve respiratory season practices, telehealth access, and pharmacist education. It will focus on COVID and other respiratory disease tests, vaccines, and antivirals.
1 min readDataMEDS AI (NASDAQ:MEDS) launched the 'Health Lives Here' Community Respiratory Program to improve access to respiratory disease vaccines, diagnostics, and therapeutics in 6,500+ independent pharmacies. The program prioritizes Nuvaxovid, offers testing, telehealth, and access to FDA-approved antivirals, aiming to enhance community health, especially in rural areas. Revenue streams include vaccine sales, telehealth services, and testing.
2 min readDataMEDS AI (NASDAQ:MEDS) announced a non-binding LOI with Datavault AI (NASDAQ:DVLT), others, to acquire QOLPOM IP and expand its healthcare ecosystem. The deal aims to integrate health tracking, prescription delivery, and AI/blockchain tech, with a Q4 2026 target close. FDA guidance supports the optimization of DataMEDS' Health Lives Here app. The transaction is subject to due diligence and regulatory approvals.
3 min readDataMeds AI, Inc. (MEDS) filed an SEC Form 8-K — Other Events. Exhibit 99.1 PRESS RELEASE DATAMEDS AI, INC. (DBA DATAMEDS SI) 3000 BAYPORT DRIVE, SUITE 950 TAMPA, FLA. 33607 www.datamedsai.com RUBENSTEIN PUBLIC RELATIONS CONTACT: JAMES LAMBERT 212-805-3024 JLAMBERT@RUBENSTEINPR.COM FOR IMMEDIATE RELEASE DATAMEDS REGAINS COMPLIANCE WITH NASDA
2 min readDataMeds AI (NASDAQ:MEDS) announced it has regained compliance with NASDAQ's minimum stockholders' equity requirement of $2.5 million. The company previously faced delisting for failing to meet this threshold and a $1 bid price. NASDAQ confirmed compliance after recent Form 8-K filings showed equity exceeding $2.5 million. Continued compliance depends on future periodic reports.
1 min readDataMeds AI Inc. (NASDAQ: MEDS) stock surged 16.32% after securing Humana Medicaid coverage for its ChemoFx assay and reporting $1M in September revenue. The company also launched a GLP-1 focused app, driving investor interest. Despite weak fundamentals, including negative cash flow and equity, MEDS trades on news catalysts, with significant volatility.
3 min read
